Article info

Download PDFPDF
A Phase I-II Evaluation of Veliparib (NSC #737664), Topotecan, and Filgrastim or Pegfilgrastim in the Treatment of Persistent or Recurrent Carcinoma of the Uterine Cervix: An NRG Oncology/Gynecologic Oncology Group Study

Authors

  1. Address correspondence and reprint requests to Charles Kunos, MD, PhD, Department of Radiation Oncology, Summa Cancer Institute, 161 N Forge St, Akron, OH 44304. E-mail: kunosc@summahealth.org.

Citation

Kunos C, Deng W, Dawson D, et al
A Phase I-II Evaluation of Veliparib (NSC #737664), Topotecan, and Filgrastim or Pegfilgrastim in the Treatment of Persistent or Recurrent Carcinoma of the Uterine Cervix: An NRG Oncology/Gynecologic Oncology Group Study

Publication history

  • Received October 27, 2014
  • First published March 1, 2015.
Online issue publication 
March 01, 2015

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.